MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice
Open Access
- 12 June 2024
- journal article
- research article
- Published by Elsevier in Journal of Lipid Research
- Vol. 65 (7) , 100576
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Association of hypercholesterolemia or hypertriglyceridemia with degree of hepatic steatosis in patients with non-alcoholic fatty liver diseaseClinical Nutrition ESPEN, 2021
- MicroRNA‐206 enhances antitumor immunity by disrupting the communication between malignant hepatocytes and regulatory T cells in c‐Myc miceHepatology, 2021
- Bile Acid Homeostasis in a Cholesterol 7α‐Hydroxylase and Sterol 27‐Hydroxylase Double Knockout Mouse ModelHepatology, 2019
- LXRα Promotes Hepatosteatosis in Part Through Activation of MicroRNA‐378 Transcription and Inhibition of Ppargc1β ExpressionHepatology, 2019
- MicroRNA‐206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto‐oncogene and cyclin‐dependent kinase 6 in miceHepatology, 2017
- Mapping the Human miRNA Interactome by CLASH Reveals Frequent Noncanonical BindingCell, 2013
- Malondialdehyde (MDA) and protein carbonyl (PCO) levels as biomarkers of oxidative stress in subjects with familial hypercholesterolemiaClinical Biochemistry, 2010
- Molecular basis of PCSK9 functionAtherosclerosis, 2009
- Use of Minicircle Plasmids for Gene Therapy2009
- Regulation of bile acid synthesisHepatology, 1991